ACE and hydrops fetalis: Conversely, HF patients on angiotensin-converting enzyme inhibitor (ACEi) were associated with lower mean total cost of HF PPPY, compared to patients not on ACEi (USD 1,942 vs. USD 2,034, p = 0.011).